Eli Lilly
投资主体/品牌（类型待核）
Verified investment lower bound≥$4.96M
Investment cases2
Manager operating history—
Representative investments
Individual transactions and cumulative snapshots use different bases. Do not add these rows again to cumulative totals.
| Date | Company | Round | Original-currency amount | Paying entity | Specific funds | Sources |
|---|---|---|---|---|---|---|
| 2025-12-30 | Insilico Medicine（英矽智能） | IPO最终获配认购 | HKD 38.9M | Eli Lilly and Company | — | Sources · 2
Basis and notes基石1,617,500股＋额外国际配售0股，合计1,617,500股×HK$24.05。按最终配售计算认购款，不含费用，不声称银行流水已核。上市日为交易事件日期，非银行付款日。美元仅使用本站既有汇率快照；不是按当前股价计算。 |